# 바이오스페이스 일일 뉴스 리포트 - 2025년 09월 06일


## 주요 헤드라인

1. **With Lykos MDMA Rejection Letter Out, MAPS Founder Decries ‘Change of the Goal Posts’ (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/with-lykos-mdma-rejection-letter-out-maps-founder-decries-change-of-the-goal-posts>

2. **With Lykos MDMA Rejection Letter Out, MAPS Founder Decries ‘Change of the Goal Posts’ (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/with-lykos-mdma-rejection-letter-out-maps-founder-decries-change-of-the-goal-posts>

3. **Senate Hearing Devolves Into Theater as Kennedy Accused of Breaking Vaccine Promises (#뉴스)**
   - Article content not available
   <https://www.biospace.com/policy/senate-hearing-devolves-into-theater-as-kennedy-accused-of-breaking-vaccine-promises>

4. **Senate Hearing Devolves Into Theater as Kennedy Accused of Breaking Vaccine Promises (#뉴스)**
   - Article content not available
   <https://www.biospace.com/policy/senate-hearing-devolves-into-theater-as-kennedy-accused-of-breaking-vaccine-promises>

5. **Monarez Blasts Partisan Public Health Policy at CDC Under RFK Jr. (#뉴스)**
   - Article content not available
   <https://www.biospace.com/policy/monarez-blasts-partisan-public-health-policy-at-cdc-under-rfk-jr>

6. **Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/sanofis-anti-ox40-blocker-falls-well-below-expectations-in-phase-iii-eczema-study>

7. **Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+ (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/hengrui-licenses-heart-disease-drug-to-us-startup-for-up-to-1b>


---
*2025년 09월 06일 바이오스페이스 뉴스 피드에서 생성된 리포트*